Key facts
- This page summarizes Sharon Shacham's Form 4 filing for Acrivon Therapeutics, Inc. (ACRV).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 20 May 2026, 16:36.
Sharon Shacham - 18 May 2026 Form 4 Insider Report for Acrivon Therapeutics, Inc. (ACRV)
- Reporting relationship
- Director
- Issuer ticker
- ACRV
- Reported as of
- 18 May 2026
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 20 May 2026, 16:36:13 UTC
- Prior SEC filing
- 27 Mar 2026
- Next SEC filing
- 22 Jun 2026
- Source filing
- View source filing
- Reporting owner signature
- /s/ Adam D. Levy, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Sharon Shacham filed Form 4 for Acrivon Therapeutics, Inc. (ACRV) on 20 May 2026.
Change
- Previous filing in this sequence was filed on 27 Mar 2026.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0001588438
Primary reporting owner
Shacham Sharon
- Relationship
- Director
- Address
- C/O ACRIVON THERAPEUTICS, INC., 480 ARSENAL WAY, SUITE 100, WATERTOWN
- Signature
- /s/ Adam D. Levy, Attorney-in-Fact
- Signature date
- 20 May 2026
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
ACRV
transaction
Common Stock
Award
- Transaction value
- Shares
- +9,366
- Change %
- Price
- $0.000000*
- Shares after
- 9,366
- Date
- 18 May 2026
- Ownership
- Direct
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
These shares represent restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. These RSUs shall vest in full on May 18, 2027, subject to the Reporting Person's continuous service through such vesting date.